Le Lézard
Classified in: Health
Subjects: CSR, PET, ANW

1.9 Million Doses of NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): Donated by Boehringer Ingelheim Cares Foundation to Aid Shelter Dogs in Need


DULUTH, Ga., March 15, 2024 /PRNewswire/ -- The Boehringer Ingelheim Cares Foundation, through its Product Donation Program, has made a significant contribution to animal shelters across the country. The Product Donation Program donates Boehringer Ingelheim medicines to approved nonprofit partners who distribute the medicines around the world where there is tremendous unmet need.

The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.

The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms. Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023.

The donation, valued at $42.6 million, is part of Boehringer's ongoing commitment to support animal health and wellbeing. The company partnered with Greater Good Charities, a renowned organization dedicated to improving the health and well-being of people, pets and the planet, to distribute the products to animal shelters in need.

This substantial donation will significantly impact the lives of countless dogs in shelters, providing them with essential protection against harmful parasites. Parasiticides play a crucial role in the adoption of shelter dogs by ensuring they are protected from parasites, thus enhancing their health and making them more appealing to potential adopters.

"Boehringer Ingelheim is deeply committed to safeguarding the health and wellbeing of animals in shelters," said Randolph Legg, President and Head of Commercial Business, Boehringer Ingelheim Animal Health USA and board member of the Boehringer Ingelheim Cares Foundation. "Our mission is to ensure they receive the best care possible while they patiently wait for their forever homes. This donation is a testament to our commitment and we hope it will make a significant difference in the lives of animals in need."

NexGard® PLUS Important Safety Information
NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only. The most frequently reported adverse reactions reported in clinical trials were diarrhea, vomiting, lethargy, and itching. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of NexGard® PLUS has not been evaluated in breeding, pregnant, or lactating dogs. Dogs should be tested for existing heartworm infection prior to starting a heartworm disease preventive. For more information, click here for full prescribing information, or visit NexGardPLUSClinic.com.

About Boehringer Ingelheim Animal Health USA
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.

As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long- term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.

Learn more about Boehringer Ingelheim Animal Health USA at bi-animalhealth.com

About Boehringer Ingelheim Cares Foundation
Boehringer Ingelheim Cares Foundation is an independent nonprofit organization with a mission to strengthen the communities where our employees live and work by improving the health and well-being of people and animals, with a focus on helping the underserved. The programs we support align with our goals to improve access to healthcare, enhance STEM education, and strengthen the human-animal bond.

NexGard® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0135-2024.

SOURCE Boehringer Ingelheim


These press releases may also interest you

at 01:00
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on...

at 00:30
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology...

at 00:00
The Riverside Company, a global private investor focused on the smaller end of the middle market, has closed the acquisition of Arbeidsmiljø og Energiteknikk AS (AET), a Norwegian distributor of third-party consumables and laboratory / cleaning...

at 00:00
COEUS Solutions, a leading provider of innovative technologies and services in the life sciences industry, today announces its rebranding to BridgeView Life Sciences ("BridgeView") following a recent spinoff from its former parent company. This marks...

29 avr 2024
General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive...

29 avr 2024
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders.The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction...



News published on and distributed by: